



## **Incyte to Report 2004 Financial Results and 2005 Financial Guidance; Provide Update on Discovery & Development Programs on February 28**

February 9, 2005

WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 9, 2005--Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2004 financial results conference call for 4:30 p.m. EST on Monday, February 28, 2005. The schedules for the press release and conference call are as follows:

Q4 & YE 2004 Press Release: February 28, 2005 at 4:05 p.m. EST

Q4 & YE 2004 Conference Call: February 28, 2005 at 4:30 p.m. EST

Domestic Dial In Number: 877-692-2592

International Dial In Number: 973-582-2700

Conference ID # 5701823

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-519-4471 and dial-in number for international callers is 973-341-3080. The replay pin number is 5701823.

The conference call will also be webcast live on CCBN and can be accessed at [www.incyte.com](http://www.incyte.com) under Investor Relations, Events and Webcasts.

### **About Incyte**

Incyte Corporation is a Wilmington, Delaware based drug discovery and development company with a growing pipeline of oral compounds to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset(TM), is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. The company's lead internal compound, INCB3284, is a proprietary, oral CCR2 antagonist in Phase II development that may have therapeutic value in a number of chronic inflammatory diseases. Incyte has several other early drug discovery programs.

Except for the historical information contained herein, the matters set forth in this press release, including the expected utility of the company's product candidates, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including developments affecting Incyte's research and development activities, the results of further research and development, and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2004. Incyte disclaims any intent or obligation to update these forward-looking statements.

### **CONTACT:**

Incyte Corporation  
Pamela M. Murphy, 302-498-6944

SOURCE: Incyte Corporation